Specialised Therapeutics Australia supporting OncoSil study
Filed with ASX · · 3 pages · English
• Independent pharmaceutical company Specialised Therapeutics Australia (STA) to support Oncosil Medical global Pancreatic Cancer study • STA to supply subsidised ABRAXANE(nanoparticle albumin-bound paclitaxel) to Australian sites for clinical study • ABRAXANEis marketed in Australia by STA under license from Celgene Corporation • Majority of patients recruited at five key Australian trial sites
Earlier from OncoSil Medical
- US IRB Approval, MD Anderson Cancer Centre
- UK Central Ethics Approval
- First subject recruited
- Appendix 4D & Half Year Accounts
- MHRA Approval to commence study in UK
Later from OncoSil Medical
- First OncoSil Device Implantation procedure completed
- Appendix 4C and Quarterly update
- Second subject recruited at Monash Health Melbourne
- CE Mark & Quarterly Activity Update
- First UK subject recruited
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical